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Abstract
Most Bayesian response-adaptive designs unbalance randomization rates
towards the most promising arms with the goal of increasing the num-
ber of positive treatment outcomes during the study, even though the
primary aim of the trial is different. We discuss Bayesian uncertainty
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directed designs (BUD), a class of Bayesian designs in which the inves-
tigator specifies an information measure tailored to the experiment. All
decisions during the trial are selected to optimize the available infor-
mation at the end of the study. The approach can be applied to several
designs, ranging from early stage multi-arm trials to biomarker-driven
and multi-endpoint studies. We discuss the asymptotic limit of the
patient allocation proportion to treatments, and illustrate the finite-
sample operating characteristics of BUD designs through examples,
including multi-arm trials, biomarker-stratified trials, and trials with
multiple co-primary endpoints.
Keywords: Multi-arm clinical trials, Information theory, Decision
theory, Response-adaptive designs.
1 Introduction
We discuss a class of Bayesian adaptive designs for randomized clinical trials
that seek to maximize the acquisition of information on the effectiveness of
new experimental treatments. We call this class of designs Bayesian uncer-
tainty directed (BUD) designs. For a BUD design, the investigator specifies
a Bayesian model that will be continuously updated during the trial and a
metric to quantify the accumulated information on experimental treatments.
This information measure is a summary of the posterior distribution, and
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all decisions during the trial are selected to approximately optimize the
available information on experimental treatments at the end of the study.
We illustrate the approach through examples, including controlled multi-
arm trials, biomarker-defined subgroup trials [39], and trials with multiple
co-primary endpoints [25].
Adaptive designs for clinical experiments use the accumulating data dur-
ing the study to modify characteristics of the ongoing trial [7, 33]. For in-
stance patient eligibility can be modified during the study, the overall sample
size may be re-estimated at interim analyses, or randomization probabili-
ties can be unbalanced towards the most promising arms [35, 21, 38, 39].
Adaptive designs have been applied in several settings, ranging from dose
finding studies to Phase III trials [29, 1, 20, 12, 13]. These designs have been
developed to save resources, to protect patients from ineffective treatments,
and to gain efficiency in the development of new treatments.
For most clinical studies one can consider multiple designs, including
adaptive randomization [7]. Practitioners can compare and select from
competing candidate methodologies. Selecting according to interpretable
performance criteria is desirable [42, 41], and it forces the investigator to
explicitly specify the primary aims of the trial. The Bayesian decision-
theoretic framework identifies the design that maximizes the performance
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criteria in expectation. The approach enables the use of utility functions u
to represent investigator preferences and it incorporates a priori information
into the design through Bayesian modeling [2]. The utility u = u(Y, θ, d)
is a random function of the unknown parameters θ, for instance response
probabilities that one seeks to estimate during the trial, and of the data Y
collected during the study using the design d. Bayesian designs maximize
the utility in expectation.
Bandit problems have been studied extensively in the context of clinical
trials [5, 6, 23, 14, 46, 40]. A multi-arm Bandit problem describes a sequen-
tial decision process. At each stage of the process, a decision maker chooses
to “play” one of K arms, this arm then generates a random outcome and
a corresponding payoff. In a clinical trial, the arms typically correspond to
K treatments, and the outcome summarizes the response of a patient to
the assigned treatment. In a Bandit problem the decision maker seeks to
select arms during the trial to maximize the total payoff of the sequential
experiment [5]. This class of decision-theoretic designs can be used to max-
imize an explicit utility in expectation, for instance the expected number of
responders at the end of the trial. The solution of a Bandit problem is the
sequence of decisions that maximizes the expected payoff, and in some cases
it can be computed with backward induction (BI) [2].
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It has been well documented that BI is often computationally prohibitive
[2], and several approximation strategies have been suggested. For instance,
Carlin et al. [11] introduced a forward sampling algorithm. Alternative
algorithms [19, 9, 24] approximate Bandit solutions by combining forward
sampling with backward induction. M-steps myopic look-ahead procedures,
which select at each state the action that maximizes the expected utility
at completion of a fictitious M-stages horizon, have been discussed in [10].
These procedures can be extended to allow for randomized actions [28]. In-
deed randomization is often a requirement in clinical trials. In these cases,
for each patient an arm a is randomly assigned, with randomization prob-
abilities chosen within a fixed and pre-specified subset of the simplex, to
optimize the payoff at M-stages.
Popular Bayesian designs, including Bayesian adaptive randomization
(BAR) [35], unbalance randomization probabilities towards the most promis-
ing arms. These designs appear consistent with the goal of maximizing the
number of positive treatment outcomes during the study, although the pri-
mary aim of the trial could be different. Here we focus on uncertainty
directed designs for clinical trials. Figure 1 illustrates relevant differences
between the randomization probabilities of BUD and BAR designs. In this
figure each panel summarizes the posterior distribution for a 3-arm trial
5
(without control) with the primary goal of selecting the most effective treat-
ment.
BUD designs use information measures that are convex functionals of
the posterior distribution p(θ | Y ). Examples will include the entropy of
the posterior probability of a positive treatment effect H(I(γa(θ) > 0) | Y )
for an experimental arm a, and the posterior variance of treatment effects
Var(γa(θ) | Y ). The use of a convex measure ensures — by straightforward
arguments based on Jensen’s inequality — that, on average, information in-
creases with every additional observation. In a BUD design decisions during
the trial are selected to maximize these information increments. Using sim-
ulations, we show that in multi-arm studies, the operating characteristics of
BUD designs are comparable to decision-theoretic designs derived through
BI when the corresponding utility function u and information metric coin-
cide.
The paper is structured as follows. Section 2 introduces BUD designs and
illustrates their asymptotic behavior with two specific examples. Section 3
examines the operating characteristics of BUD designs for multi-arm trials.
Section 4 discusses BUD designs for biomarker-defined subpopulation trials.
The aim here is to match targeted treatments with subgroups of patients that
benefit from them. Section 5 deals with an application of the BUD approach
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to a multi-arm trial with several co-primary endpoints [25]. We conclude
the paper with a discussion in Section 6. Details on the computational
implementation of the methods proposed and R functions are provided in
the supplementary material.
2 Bayesian Uncertainty Directed Designs
In the decision-theoretic framework for sequential experiments the investiga-
tor specifies a probability model for unknown parameters and observations
during the trial. At pre-planned stages, the experiment can be modified
by selecting actions, which may correspond for example to the decision to
close the enrollment for a patient subgroup or to modify the randomization
probabilities.
The decision maker selects, at stages t = 1, . . . , T , an action At from a
set A in a sequential manner. Each action At, in turn, generates a random
outcome Yt ∼ p(Yt | At, θ) with value in Y. We use a prior probability for
the parameters θ ∈ Θ of the outcome distribution. The action taken at
time t + 1 is a random variable At+1, whose distribution depends on the
history of previous actions and outcomes Σt = {(A`, Y`), ` ≤ t}. We write
At+1 = d(Σt) to make this dependence explicit. In different words, previous
actions and outcomes Σt are translated either into the selection of a point
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in A, for instance the selection of a specific arm, or into a distribution over
A, for example the randomization probabilities for patients that will be
enrolled.
Several authors proposed and justified multi-stage designs using utility
functions [18]. In a two-stage single-arm trial with binary endpoints with
nt patients for stages t = 1, 2, the actions (A2, A3) ∈ {0, 1}2 represent
the decisions (i) to continue the trial after the first interim analysis if the
number of responses is sufficiently promising A2 = d(Σ1) = I(Y1 > y1),
and subsequently (ii) to recommend the treatment for a confirmatory trial
if more than y2 > 0 responses have been observed during the trial, A3 =
d(Σ2) = I(Y1 > y1) × I(Y1 + Y2 > y2). In the example Yt is a binomial
random variable with size nt and probability θ.
For a given experiment, we let D denote the set of decision functions that
map the data into actions. For the two-stage design D can be identified by
varying the thresholds (y1, y2) ∈ {0, . . . , n1}×{0, . . . , n1 +n2}. Throughout
the article u(d, Y, θ) indicates the utility function. It is a random quantity,
which is a function of the parameter θ and the data Y generated under
design d ∈ D. A rational investigator selects the design d from D that
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maximizes the expected utility U(d) = E[u(d, Y, θ)] of the experiment [2],
d? = arg max
d∈D
U(d). (1)
In some cases d? can be computed exactly using backward induction (BI)
[2], but this is often infeasible. The two-arm bandit problem with binary
outcomes, as described in [5, 14], is a good example to describe how quickly
the computational burden of the BI algorithm increases with the sample size.
For a trial with 50 observations, the BI algorithm requires
(
54
4
)
= 316, 251
operations dedicated to each possible configuration of the sufficient statis-
tics, these are the combinations of positive and negative outcomes for each
arm after t = 0, 1, · · · , T assignments. The number of operations increases
quickly with the sample size, for instance, by doubling the sample size the
number of operations increases to
(
104
4
)
= 4, 598, 126. Strictly related con-
siderations have been discussed for biomarker trials in [46].
We focus therefore on a myopic approximation of d? [2], and proceed in
three steps:
Step (1) - Action space: We first specify the set of actions A that can
be selected at each of the T stages of the experiment. For example, in a
controlled two-arm trial, which randomizes n patients during each stage t,
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the action At is the number of patients assigned to the experimental arm.
Hence, A = {0, 1, . . . , n}. The randomization probability rt ∈ (0, 1) toward
the experimental arm is a function of the history of actions and outcomes
Σt−1, and At | Σt−1 ∼ Binomial(n, rt).
Step (2) - Information metric: Next we quantify the acquired information
through the accumulated data Σt until stage t. Our utility function u(·) will
quantify the information accrued by the experiment. Large values of u(Σt)
correspond to low uncertainty levels. We use functions u˜ that translate the
posterior p(θ ∈ · | Σt) into utilities, i.e. u(Σt) = u˜(p(θ ∈ · | Σt)). The utility
functions u can have negative values. In the next paragraphs we provide
some examples:
(i) Multi-arm trials: Consider a multi-arm study with binary endpoints
and primary aim of providing accurate estimates of the treatment ef-
fects γa for the effective experimental treatments a with γa > 0. Here
γa = θa − θ0 is the difference between the response probability θa for
treatment a and the control arm. We can define
u(Σt) =
K∑
a=1
(
va −Var(γa × I(γa > 0) | Σt)
)
(2)
to measure information up to stage t, with va = Var(γa × I(γa > 0))
10
denoting the prior variance.
(ii) Biomarker-stratified trial: We test K treatments for patients with
and without a genomic alteration. The trial will measure binary out-
comes with parameters θx,a for subgroups x = 0, 1 and treatments
a = 0, . . . ,K. The primary aim is to test the presence of effects
within subgroups Ex,a = I(θx,a > θx,0) and in the overall popula-
tion Ea = I(θa > θ0). Here θa = βθ1,a + (1 − β)θ0,a and β ∈ [0, 1]
is the prevalence of the biomarker. Let H[p(X)] = −E[log p(X)] indi-
cate the entropy of a random variable X. We can use a summary u
that weights the entropy values associated to interpretable posterior
probabilities,
u(Σt) = −
K∑
a=1
{
H[p(Ea | Σt)]+w×
(
H[p(E1,a | Σt)]+H[p(E0,a | Σt)]
)}
, with w ≥ 0.
(iii) Dose-finding trial: We select one of K candidate dose levels A =
{1, 2, . . . ,K} using binary efficacy and toxicity outcomes. We let θE,a
and θT,a denote the probabilities of response and toxicity at dose level
a. For each dose level a a score weights efficacy θE,a and toxicity
θT,a, say Sa(θ) = wθE,a + (1 − w)(1 − θT,a) with 0 ≤ w ≤ 1 and
dose level A? = arg max
a
Sa(θ) has the highest score. In Bayesian
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modeling (θE,a, θT,a)a, as well as Sa(θ) and A?, are random vari-
ables. The posterior distribution p(A? = a|Σt) = p
( ∩a′ {Sa(θ) ≥
Sa′(θ)}|Σt
)
, a = 1, · · · ,K, changes over time as more information be-
comes available. We can use the (negative) entropy of the posterior
and specify u(Σt) =
∑
a p(A
? = a|Σt) log p(A? = a|Σt).
For each example we only mention one information metric tailored to the
aim of the trial. Several alternative measures u could be used. The unifying
element is the use of functionals of the posterior to quantify information.
Step (3) - Myopic approximation: As we mentioned the information metric
u˜ is specified by a convex functional over the convex space of distributions
on Θ. In different words
u˜(w × p1 + (1− w)× p2) ≤ w × u˜(p1) + (1− w)× u˜(p2)
for every pair of probability measures p1 and p2, when w ∈ [0, 1]. Let
u(Σt) = u˜(p(θ ∈ · | Σt)) be the current value of the information function.
By Jensen’s inequality, given the action selected at the next step At+1 = a,
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the information on average increases
E[u(Σt+1) | Σt, At+1 = a] = E[u˜(p(· | Σt+1)) | Σt, At+1 = a]
≥ u˜(E[p(· | Σt+1) | Σt, At+1 = a]) = u(Σt). (3)
It is desirable for u˜ to satisfy this inequality, as any additional observation
should tend to reduce uncertainty.
BUD designs select actions that generate large information increments.
The myopic decision rule d˜ ∈ D selects at each stage the action that max-
imizes the gain of information At+1 = d˜(Σt) = arg maxa∈A∆t(a), where
∆t(a) = E[u(Σt+1) | At+1 = a,Σt] − u(Σt) ≥ 0. In most clinical trials,
non-randomized policies like the myopic decision rule described above, are
inappropriate [8]. For this reason we use the BUD design dBUD, which is
a randomized version of the myopic design. The design translates Σt into
a distribution on A. In particular, if At+1 is the treatment assigned to the
next patient, then
p(At+1 = a | Σt) ∝ ∆t(a)h(t). (4)
Here h(·) is a non negative function. With large values of h(t) the the
BUD design dBUD and the myopic design d˜ become nearly identical. On
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the other extreme, with h(t) = 0, the randomization probabilities become
identical across arms. The choice of h(·) has the goals of (i) satisfying the
requirement to randomize patients and (ii) the approximate optimization of
utility criteria u.
2.1 Asymptotic Allocation Proportions in BUD Designs
Our goal is the study of BUD designs with realistic sample sizes (Sections
3–5). However, understanding the asymptotic behavior of BUD policies is
useful to interpret simulation results and to ascertain if the proportions of
patients allocated to different arms converges to a nearly optimal limit. Here
we discuss with examples asymptotic characteristics of BUD designs. For
simplicity we consider a constant parameter h(·) = h ≥ 0 in (4).
Lemma 1 is a technical result that we will later use to derive asymp-
totic allocation proportions in two examples. A proof following stochastic
approximation arguments can be found in the appendix. Let p̂a,t be the
proportion of samples allocated to arm a by time t.
Lemma 1. Consider the allocation of patients to arms A = {0, 1} with a
BUD design. Define Ft = −p̂0,t + ∆ht (0)/(∆ht (0) + ∆ht (1)). Suppose that, on
a set of probability 1, for any ε > 0 there is a random time T , and number
c > 0 such that Ft < −c wherever p̂0,t > ρ0 + ε, and Ft > c wherever
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p̂0,t < ρ0 − ε for all t > T . Then p̂0,t → ρ0 a.s.
Remark 1. Before applying this result to examples, we observe that for
some utility criteria u it is straightforward to extend the lemma to ex-
periments with multiple arms A = {0, . . . ,K}. In particular, when the
information metric u(Σt) is an additive functional of the posterior of each
parameter θa, a ∈ A, for example u(Σt) = −
∑
a Var(θa | Σt), the informa-
tion gain ∆t(a) depends only on the prediction of outcomes from a single
arm a. For any pair of arms (a1, a2), the subsequence of samples assigned
to these two arms is equivalent to a two-arm BUD design. Therefore, if the
conditions of Lemma 1 hold,
p̂a1,t
p̂a1,t + p̂a2,t
a.s.→ ρ˜a1,a2
for every a1, a2 ∈ A. Then, the allocation proportions (p̂0,t, . . . , p̂K,t) con-
verge to a limit ρ = (ρ0, . . . , ρK), which is the unique solution to the linear
system
K∑
a=0
ρa = 1 , ρa1 = ρ˜a1,a2(ρa1 + ρa2) for all {a1, a2} ⊂ {0, . . . ,K}.
Example 1. Multi-arm trial with normal outcomes. Assume the
outcome Yt | At = a ∼ N(θa, σ2a) is normal with unknown mean θa and
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known variance σ2a. We use independent N(0, σ
2) prior distributions for θa,
a ∈ A = {0, . . . ,K} and show that in a BUD design, driven by the informa-
tion measure
u(Σt) = −
K∑
a=0
Var(θa | Σt) = −
K∑
a=0
1
σ−2 + tp̂a,t × σ−2a
,
the arm-specific sample size proportions converge a.s. to
ρa =
σ
2h
1+2h
a∑K
`=0 σ
2h
1+2h
`
for all a = 0, . . . ,K. (5)
For large h the BUD design becomes nearly identical to the myopic design,
and the limit (5) coincides with the Neyman allocation ρa ∝ σa [17].
To show the convergence to (5), we note that the information gain ∆t(a)
is equal to
∆t(a) =
1
σ−2 + tp̂a,tσ−2a
− 1
σ−2 + (tp̂a,t + 1)σ−2a
=
σ2a
(σ2a/σ
2 + tp̂a,t)(σ2a/σ
2 + 1 + tp̂a,t)
=
σ2a
t2p̂2a,t
+O((p̂a,tt)−3).
(6)
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Using (6), we can write
Ft = −p̂0,t + ∆
h
t (0)
∆ht (0) + ∆
h
t (1)
= −p̂0,t +
(
p̂−20,tσ
2
0 +O(t−1p̂−30,t )
)h
(
p̂−20,tσ20 +O(t−1p̂−30,t )
)h
+
(
p̂−21,tσ21 +O(t−1p̂−31,t )
)h .
(7)
Consider a similar sequence
F˜t = −p̂0,t +
p̂−2h0,t σ
2h
0
p̂−2h0,t σ2h0 + (1− p̂0,t)−2hσ2h1
. (8)
Note that F˜t is strictly decreasing in p̂0,t ∈ [0, 1] with a zero at ρ0, which
implies that for any ε > 0 there is a c > 0 satisfying F˜t < −c wherever
p̂0,t > ρ0 + ε, and F˜t > c wherever p̂0,t < ρ0 − ε. These are the assumptions
of Lemma 1.
We need to show that Ft − F˜t → 0 as t → ∞ to apply the lemma
and derive (5). First, consider the Ft subsequence when t
−1/3+δ < p̂0,t <
1 − t−1/3+δ for some δ ∈ (0, 1/3). In this case p̂0,t does not approach zero
or one too quickly, and the difference between (7) and (8) vanishes for large
t. Second, when p̂0,t ≤ t−1/3+δ, it can be verified that ∆t(1)/∆t(0) → 0 as
t→∞, and that Ft → 1. Conversely, when p̂0,t > 1− t−1/3+δ, Ft → −1. We
can therefore apply the lemma to conclude that p̂0,t → ρ0. For a multi-arm
BUD design, K > 1, it is sufficient to apply Remark 1.
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Example 2. Multi-arm trial with binary outcomes. Now consider
the case where Yt is binary with p(Yt = 1 | At = a) = θa, and a prior
θa ∼ Beta(α, β) for a ∈ A. We consider the same information metric of
the previous example and prove that the allocation proportions converge
with probability 1 to the limit in (5) with σ2a = θa(1− θa). In this example,
the information gain ∆t(a) has a closed-form expression which simplifies the
derivation of the asymptotic result. The proof follows the same arguments
of the previous example, and it is deferred to the appendix.
The examples above are by no means exhaustive, but their simplicity per-
mits a self-contained analysis, which points to mathematical techniques. An
important case not covered here is that of BUD designs in which the utility
function u is not additive on the treatment arms. The information metric (2)
in Section 2 is an example where Lemma 1 is not directly applicable. Such
information metics are of practical relevance, for example when some of the
experimental agents are potentially significantly inferior to the standard of
care. We believe that the extensive literature on stochastic approximation
can be used for additional asymptotic analyses of BUD designs, including
non additive utilities u. The monograph [26] provides a useful guide. The
general strategy would consist of writing the vector of allocation propor-
tions (p̂0:K,t)t≥0 as a stochastic approximation process; namely, one would
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express the increments p̂0:K,t+1 − p̂0:K,t = γt(F (p̂0:K,t) + t+1 +O(t−1)) for
some sequences (t)t≥0 and (γt)t≥0 with E[t+1 | Σt] = 0,
∑
t γt = ∞, and∑
t γt/t <∞. Then the arguments used to prove Lemma 1 can be adapted to
establish that {p̂0:K,t}t∈N approaches the solution of a differential equation.
3 BUD Designs for Phase II Multi-Arm Trials
We discuss BUD designs for two multi-arm Phase II trials with distinct aims:
(i) to identify all experimental arms with a positive treatment effect [43],
and (ii) to select the treatment with the most favorable outcome distribution
[30].
3.1 Estimation of Treatment Effects in a Controlled Multi-
Arm Study
We first considered a study with K experimental arms compared to a control
therapy. For each patient t, action At = a, with a ∈ A = {0, . . . ,K},
indicates the assignment of patient t to arm a, where a = 0 denotes the
control arm. The primary outcome is the binary response to treatment with
probability of response p(Yt = 1 | At = a, θ) = θa, a = 0, . . . ,K. We use
independent beta random variables θa ∼ Beta(θa; v1, v2) for a = 1, · · · ,K
to define the prior for θ = (θ0, . . . , θK).
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The trial is designed to generate estimates of the treatment effects, γa,
with low posterior variance at the end of the trial. We use an information
measure which is consistent with this goal,
u(Σt) =
K∑
a=1
(
va −Var(γa | Σt)
)
, (9)
where va = Var(γa). When the primary goal is to test the null hypothesis
H0,a : γa ≤ 0, a slightly different utility function −Var(g(γa) | Σt) can be
considered, where g : [−1, 1] → [0, 1] is a monotone function with plateaus.
Each patient is assigned to treatment a ∈ A with probability
p(At+1 = a | Σt) ∝
(
K∑
a′=1
E
[
va′ −Var(γa′ | Σt+1)
∣∣ At+1 = a,Σt]− u(Σt))h(t).
(10)
Simulation Study: We discuss results of a simulation study for a 4-arm
trial using the information measure (9) to estimate treatment effects. We
considered four scenarios with constant response rate of 0.4 for the control
arm (see Table 1) and use uniform prior v1 = v2 = 1 for θa, a = 0, · · · , 3. In
Scenario 1 all experimental arms are ineffective with response rates equal to
0.4. Whereas in the other scenarios some of the arms have positive treatment
effects. To simplify comparison to balanced randomization (BR) we set
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T = 336, because a BR design with one-sided Fisher’s exact test and type
I and II error rates of 0.05 and 0.20 for the alternative 0.6 vs 0.4 requires
84 patients per arm. We compare the BUD design to three alternative
randomization methods: BR, Bayesian adaptive randomization (BAR) as
described in [38], and the doubly adaptive coin design (DBCD) [16] targeting
assignment frequencies equal to the Neyman allocation ρa ∝
√
θa(1− θa)
(DBCD1) or equal to ρa ∝
√
θa (DBCD2) [16].
Table 1 shows the average number of patients randomized to each arm
across 5,000 simulations and the mean squared error (MSE) of the treatment
effect estimates. We also show the power of Fisher’s exact test (without
correcting for adaptivity [3]) for the null hypothesis H0,a : γa ≤ 0. Most
notable, among all five designs, the BUD design has the lowest MSEs for
all experimental arms across all four scenarios. When all experimental arms
are ineffective BR, DBCD1 and DBCD2 randomize on average 84 patients
to each arm with standard deviations (SDs) of 8, 4 and 6. BAR and the
BUD design randomize more patients to the control arm compared to the
remaining designs (118, 97). For BAR this is expected by construction of
the randomization probabilities [38]. In the BUD design, the assignment of a
patient to the control arm reduces the uncertainty on θ0 and therefore leads
to uncertainty reductions for all treatment effects γa = θa−θ0, a = 1, . . . ,K,
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while the assignment of a patient to arm a, a > 0, reduces the expected
variance only of θa and γa.
When only arm 1 has a treatment effect (Scenario 2), BAR assigns on
average 103 and 100 patients to arm 1 and the control arm (SD 10 and 14)
and has 87.5% power. The BUD, DBCD1 and DBCD1 designs have 82.2%,
79.8% and 81.2% power respectively, and for all three designs the standard
deviation of the number of enrolments to arm a = 0, . . . ,K is substantially
smaller than for BAR. The utility function (9) targets treatment effect es-
timates with low uncertainty. One can therefore expect similar numbers
of patients assigned to each experimental arm. In contrast with BAR the
arm-specific sample sizes tend to be markedly different across experimental
treatments. In the sections 3.2, 4 and 5 we discuss BUD designs driven by
different information measures that, similar to BAR, tend to increase the
sample size of the best experimental arms.
We also compare the BUD design to an alternative Bayesian design
[35] (BAR2) which assigns patients to arms with probability proportional
to p(θa > θa′ for a
′ 6= a|Σt)t/(2T ). Compared to the BUD and BAR de-
signs, BAR2 assigns more patients on average to the most effective arm,
(84, 161, 180, 130) assignments for BAR2 in scenarios 1 to 4 compared to
(80, 103, 117, 83) for BAR and (73, 73, 75, 70) for the BUD design, respec-
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tively. BAR2 tends to have larger MSEs for treatment effect estimates
compared to the BUD and BAR designs. For example, the MSEs of arm 3
in Scenarios 1 to 4 equal 7.3, 9.7, 10 and 9.9 for BAR2 compared to 5.5, 5.4,
4.7 and 5.1 for the BUD design.
We further investigated the behavior of BUD design by repeating the
simulations over a range of sample sizes T . In this comparison we also
included, for each scenario, a hypothetical oracle design. For a fixed to-
tal sample size T , the oracle design is defined by the number of patients
that should be assigned to each experimental arm (with sum equal to T )
in order to maximize u(ΣT ) in expectation, assuming that the oracle knows
θ. We computed for each scenario and T = 1, . . . , 200, the combination of
sample sizes {Ta}Ka=0, T =
∑
0≤a≤K Ta, that minimizes the expected value
of
∑K
a=1 Var(γa | ΣT ). The top row of Figure 2 shows, for each scenario,
the difference between the expected information Ed[u(ΣT )] of the four ran-
domization methods and the expected information of the oracle design for
different values of T . For the BUD design we observe the lowest regret
values across all sample sizes T = 1, . . . , 200. This is expected because the
BUD design, unlike the other designs, is driven by the utility u, which is
also used to define regret values. We observe that the regret of the BUD
design is considerably closer to the benchmark utilities of the oracle design
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compared to the other designs, and that the discrepancy between the BUD
design and the benchmark vanishes quickly as the sample size increases.
We also explore the sensitivity of BUD designs to different information
measures that are consistent with the study aims. We used the same sce-
narios as in the previous paragraphs and consider BUD designs defined by
the entropy, −∑Ka=1 Ep(γa|Σt)[log p(γa|Σt)] (BUD-E), the sum of the mean
absolute error of treatment effects estimates (BUD-MAD), or the poste-
rior variance and entropy of the discretized treatment effect γca (BUD-DV
and BUD-DE), which is defined as γca = 0, 1, or 2 when the treatment ef-
fect γa falls into the intervals (−1, 0], (0, 0.25] or [0.25, 1]. Table ?? in the
supplementary material shows the mean squared error (MSE), the average
number of enrollments per arm and power for these BUD designs. The de-
signs BUD-E and BUD-MAD have similar MSEs for the treatment effect
estimates across scenarios and assign on average a similar number of pa-
tients to each treatment arm. By contrast, the truncation of the treatment
effect in BUD-DE and BUD-DV increases the variability of treatment effect
estimates across scenarios.
In the supplementary material we add to these comparisons the evalu-
ation of alternative BUD designs for controlled multi-arm trials where the
utility u is representative of different study aims. The supplementary mate-
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rial includes a sensitivity analysis (Table ??) of the BUD design to variations
of the prior model.
3.2 Selection of the Best Experimental Treatment
Companies and investigators often explore multiple experimental treatments
within a single study to select the best treatments [30]. We consider a K-arm
study without control arm to identify treatment a? = arg max
1≤a≤K
θa.
The trial estimates the response rate θa? of the most effective therapy
a? with posterior distribution θa?
pθa? (x | Σt) =
K∑
a=1
[
pθa(x | Σt)
∏
j 6=a
p(θj ≤ x | Σt)
]
for x ∈ (0, 1).
Patients are randomized with the aim to minimize uncertainty on θa? . Note
that a BUD design can minimize uncertainty on a?, or it can minimize
uncertainty on the unknown response rate θa? .
We use a utility function that is consistent with the aim of minimizing
uncertainty on θa? and measure information using the (negative) posterior
entropy of θa? , H[p(θa? | Σt)] =
∫ 1
0 pθa? (z | Σt) log pθa? (z | Σt)dz. Other
measures, such as the posterior variance of θa? can be considered. When the
primary goal is to select arm a? one may specify u equal to the entropy of
the posterior distribution p(a?|Σt).
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Using the randomization scheme of section 2,
p(At+1 = a | Σt) ∝
(
E
[
H[p(θa? | Σt+1]
∣∣∣Σt, At+1 = a]−H[p(θa? | Σt)])h(t).
Simulation Study: We conducted a simulation study for a 4-arm trial that
selects the most effective treatment. We consider three scenarios (see Table
2). Arm 4 is the most effective treatment in all scenarios. We compare the
BUD design to BR, BAR (using Thomson’s rule) and the randomized-play-
the-winner (RPW) design [44]. For all randomization schemes, at comple-
tion of each simulation we compute the probabilities p(θa = max
a′=1,...,4
θa′ | ΣT )
using a uniform prior for θ = (θ1, . . . , θ4) and select the arm a
? with the
highest posterior probability of being the best available treatment.
Table 2 shows the average number of patients randomized to each arm
across 10,000 simulated trials with T = 30, 50 or 70 patients, and provides
additional operating characteristics. The BUD design selects the most ef-
fective arm more frequently across simulations compared to the three alter-
native designs. In scenario 1 after T = 30 assignments, for example, in 57%
of the simulated trials the BUD design selects the right arm, compared to
52%, 56% and 53% for BR, BAR and RPW, respectively. The BUD design
assigns on average the same number of patients to each arm as BAR, but has
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lower assignment variability. BAR is also similar to the BUD design when
we consider the probabilities of selecting the best available treatment, but
it has the largest assignment variability among all randomization schemes.
As shown in the last column of Table 2, across all scenarios the BUD design
has the lowest mean squared error for the estimate of maxa θa.
We also derived optimal sequential Bayesian designs d? in (1) using BI
for comparisons. The entropy H(θa? | ΣT ) defines the utility function and
the expected utility Ed? [u(ΣT )]. We considered small sample sizes T , up
to 30 patients, for which BI is feasible. These computations were followed
by a comparison based on 105 simulated trials for BUD, BR BAR, and
the RPW designs. In each simulation, patients respond to treatments with
probabilities θ = (θ1, . . . , θ4) ∼ p(θ) from the prior (independent beta) that
we used to compute d?. We estimate the expected utility of each design d
and the regret Ed? [u(ΣT )]−Ed[u(ΣT )], see Figure ??. The regret of the BUD
design remains close to zero across all sample sizes T that we considered,
whereas the regret of BR and RPW designs are larger; for instance the regret
for BUD, BAR, BR and RPW designs is equal to (0.014, 0.035, 0.15, 0.12)
and (0.017, 0.047, 0.30, 0.22), with T = 10 and 30 patients, respectively.
We evaluate the sensitivity of BUD designs to the choice of the random-
ization parameter h. We conducted simulations under the three scenarios
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in Table 2 using either h(t) = 1, 2, 6, 12 or 20. The parameter h in our sim-
ulations has minor influence on the resulting operating characteristics, see
supplementary Table ??. Across scenarios the average number of treatment
assignments to each arm and the proportion of simulated trials that recom-
mend the best arm for further investigation remains nearly identical when
we vary h.
4 Biomarker-Stratified Clinical Trials
The development of anti-cancer treatments focuses increasingly on therapies
that target specific genetic alterations. Consequently, there has been an in-
creasing interest in biomarker-driven studies [21, 45, 39, 37]. These studies
enroll patients with multiple genomic abnormalities in a single multi-arm
trial, and identify subgroups of patients that respond to experimental treat-
ments.
We consider a design that evaluatesK experimental therapies in biomarker
subgroups. For each patient t the vector Xt ∈ {0, 1}B defines the patients’
biomarker profile, here Xt,` = 1 if patient t has a positive marker status for
biomarker ` = 1, . . . , B and zero otherwise. In our examples B will be equal
to 2,3 or 4. Patients can be partitioned into 2B groups. We assume binary
endpoints with probability of response p(Yt = 1 | Xt = x,At = a, θ) = θx,a
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for patients with profile x ∈ {0, 1}B. Here θx,0 is the subgroup-specific
response probability for the control arm a = 0.
In oncology, treatments are commonly developed for patients with spe-
cific genomic abnormalities [27]. Pre-clinical studies typically suggest effects
of a treatment a in a targeted biomarker subgroup. But in many cases posi-
tive effects in other groups of patients are hypothesized, and treatments are
evaluated in a population larger that the target groups [27]. We assume that
treatment a > 1 targets biomarker 1 ≤ ba ≤ B, and it is therefore a priori
more likely to be effective for patients with positive biomarker Xt,ba = 1
status than for other subgroups.
The indicator E`,a = 1
( ⋃
x∈{0,1}B :xba=`
{θx,a > θx,0}
)
corresponds, for
` = 1 and 0, to treatment effects for biomarker ba positive and negative
patients, respectively. We first specify the prior probabilty p(E1,a = 1) = pi.
Since treatment effects for patients without genomic alteration ba can not
be ruled out we specify p(E0,a = 1 | E1,a = 1) = λ. Lastly, since drug a was
developed primarily for biomarker ba we assume p(E0,a = 1 | E1,a = 0) = 0.
The prior distribution for θ = (θx,a;x ∈ {0, 1}B, 0 ≤ a ≤ K) conditional
on the indicators E`,a is a product of Beta(1, 1) distributions restricted to
29
the subset R ⊂ [0, 1]B consistent with these indicators,
p
(
θ
∣∣∣E`,a; ` = 0, 1, a = 0, . . . ,K) ∝ I(θ ∈ R) ∏
x∈{0,1}B ,
a=0,...,K
Beta(θx,a ; 1, 1). (11)
Alternative prior distributions, different from the simple Bayesian model
(11) that we specified, could be applied within the BUD framework, see for
instance [45].
We define a BUD design that evaluates treatments in the targeted sub-
groups, and explores possible additional treatment effects in the biomarker
negative subgroups. The information measure is
u
(
Σt
)
=−
K∑
a=1
{
Has
[
p({E1,a = 1}∪{E0,a = 1} | Σt)
]
+
w ×
(
Has
[
p(E1,a = 1 | Σt)
]
+Has
[
p(E0,a = 1 | Σt)
])}
.
(12)
Here Has[p] = p − pβ, with β > 1, is the asymmetric entropy [22] and
w > 0 weights the information gains in the subgroups and in the overall
population. Allocations in the BUD design using (12) are driven by the
expected reduction of the posterior entropy of positive treatment effects.
The parameter β controls the curvature H ′′as[p] ∝ −pβ−2 of the entropy,
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and, using a Taylor approximation, the expected variation in the entropy
of p(E`,a = 1|Σt) given At+1 = a equals approximately
H ′′as(p(E`,a = 1|Σt))×Var[p(E`,a = 1|Σt+1)|Σt, At+1 = a]/2.
Values of β > 2 tend to reinforce the randomization probabilities of the arms
that are more promising accordingly to the posterior probabilities p(E`,a =
1|Σt) and p({E1,a = 1}∪{E0,a = 1} | Σt).
In contrast to previous BUD designs in Section 3, which focus on treat-
ment effects estimation, the metric (12) quantifies uncertainty on the pres-
ence or absence of treatment effects in biomarker targeted subgroups and
in the overall population. This is consistent with the study aim of testing
efficacy.
The BUD design assigns patients to treatment a with probability
p
(
At+1 = a | Xt+1 = x,Σt
) ∝ [E[u(Σt+1) ∣∣∣ Xt+1 = x,At = a,Σt]−u(Σt)]h(t), for a = 0, . . . ,K.
Simulation Study: Table 3 summarizes the results of a simulation study
for a controlled biomarker trial with four experimental treatments and an
overall sample size of T = 500 patients.
We considered five scenarios with four (Scenarios 1-3), three (Scenario
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4) or two (Scenario 5) biomarkers B. The true response probability for the
control equals θx,0 = 0.35 across all five scenarios and subgroups x ∈ {0, 1}B.
Treatments a = 1, . . . , 4 target biomarker ba = a in the first three scenarios.
In Scenario 1 there are no positive treatment effects (PTEs), and for all
therapies a > 0 the probabilities θx,a, x ∈ {0, 1}B are identical to the control.
Whereas in Scenarios 2-3, treatment a = 1, and treatment a = 2 (only
in Scenario 3), have PTEs with θx,a = 0.55 for all patients with positive
biomarker status for ba = a, i.e. Xt,ba = 1. In Scenario 4, treatments
a = 1, 2 both target biomarker ba = 1 and have a PTE on this subgroup with
(θx,1, θx,2) = (0.55, 0.65). The remaining treatments a = 3, 4, which target
biomarker 2 and 3, have no PTEs. Lastly, in Scenario 5, therapies a = 2, 3, 4
have PTEs in their target population ba = 1, 2, 2 with θx,a = 0.55, 0.55 and
0.65 for all biomarker positive patients Xt,ba = 1. Additionally, the PTE of
treatment a = 1 (b1 = 1) extends to all patients irrespectively of the profile
Xt = x, with θx,1 = 0.5.
We used (w, β) = (5, 6) to define the utility function of the BUD design,
and compared the design to a balanced design (BR) that randomizes patients
to the five arms with equal probabilities. For each treatment a > 0, we tested
treatment effects in the biomarker-targeted group (patients with Xi,ba = 1)
and in the biomarker negative group (Xi,ba = 0) using a bootstrap test
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similar to [38, 12, 41], accounting for adaptive randomization.
Table 3 shows mean and variability for the allocation of patients to
treatments, and the power of detecting treatment effects. The targeted
type I error rate is set at 10%. Similar to the multi-arm BUD designs in
section 3, the biomarker BUD design allocates substantially more patients
to the control arm than the BR design to reduce uncertainty on treatment
effects. This translates into a higher power across all scenarios compared to
the BR design. In Scenario 1, without treatment effects, the BUD design
assigns on average a higher number of patients with targeted biomarker
profile Xba = 1 to the corresponding experimental treatment a = 1, . . . , 4
than the BR design. It tends to match targeted treatments and biomarker
profiles. This is due to the specification of a higher a priori probability of
PTEs for the targeted biomarker-subgroups. Interestingly, in Scenario 4,
where arms a = 1 and 2 have PTEs in the first biomarker subgroup, the
BUD design on average assigns more patients to the arm with the smaller
treatment effect, which is more difficult to identify. This translates into a
gain in power of 11% compared to BR. Similarly, in Scenario 5, where all
treatments a > 1 have PTEs the BUD design randomizes on average more
patients to experimental arms with small treatment effects. This translates
into substantial gains in power compared to BR.
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In contrast to BAR, under a BUD design with utility (12), the average
arm-specific sample size is not expected to increase with the magnitude of
the treatment effect. Indeed with large treatment effects, uncertainty on
the indicators E1,a and E0,a in the targeted and non-targeted subgroups
vanishes rapidly with a limited number of observations.
We evaluated the sensitivity of the BUD design to different choices of the
parameters (β,w) which define the uncertainty function (12). We repeated
the simulations under scenarios 2 and 4 using either w = 5 with β = 2, 6, 8
or using w = 2, 5, 8 with β = 6 (Tables ?? and ??). A BUD design with
symmetric information measure β = 2 assigns on average more patients to
ineffective experimental arms than using β = 6 or β = 8. The latter two
choices have similar operating characteristic; compared to β = 2, a BUD
design with β ≥ 6 assigns on average fewer patients to ineffective agents
and increases the power by 11% for arm 1 in scenario 2, and by 5% to 9%
for arms 1 and 2 in scenario 4 (scenario 2: 74%, 86% and 85% power for
β = 2, 6, 8 using Fisher exact test). As shown in Tables ?? and ?? the BUD
design is relatively insensitive to the choice of w.
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5 Trials with Co-Primary Endpoints
In several contexts, such as Alzheimer’s disease, a single endpoint has been
shown to be insufficient to capture patients’ response to treatments ade-
quately [15]. Several authors recommend to evaluate new treatments using
multiple clinical endpoints [15]. Trial designs that evaluate treatments using
multiple outcomes have been proposed in [31, 34]. We consider a BUD design
for a controlled multi-arm trial that evaluates K experimental treatments
using two binary endpoints Yt = (Yt,1, Yt,2), for example, in Alzheimer’s
disease, the cognitive performance and the physical status after treatment.
Regulatory guidelines [15] recommend the investigator to demonstrate su-
periority of the experimental treatment a > 0 compared to the control arm
a = 0 on both endpoints.
For each treatment a, p(Yt = y | At = a) = θy,a ≥ 0, with y ∈ {0, 1}2,
and
∑
y∈{0,1}2 θy,a = 1. We use independent Dirichlet prior distributions
for the arm-specific parameters θa =
(
θ(1,1),a, θ(1,0),a, θ(0,1),a, θ(0,0),a
)
. The
parameters θa specify the marginal probabilities (ν1,a, ν2,a) of the two end-
points. We use γ`,a = ν`,a − ν`,0, ` = 1, 2, to indicate treatment effects for
both endpoints, and define the indicators E`,a = 1{γ`,a > 0}, ` = 1, 2, and
Ea = E1,a × E2,a.
The posterior probability p(Ea = 1 | Σt) summarizes the available evi-
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dence of therapy a as suitable alternative to the control therapy. Although
the investigator’s focus is on testing Ea = 0 versus Ea = 1, improvements for
one of the two outcomes are also relevant. We therefore consider a composite
uncertainty measure
u1(Σt) = −
K∑
a=1
{
Has[p(Ea = 1|Σt)]+w×
(
Has[p(E1,a = 1|Σt)]+Has[p(E2,a = 1|Σt)]
)}
,
(13)
where as before Has[p] = p − pβ, β > 1 and w > 0, which is consistent
with the study goals of testing Ea and improvements for single endpoints
Ea,`, ` = 1, 2.
To explore variations of the BUD design’s operating characteristics with
different information measures we also considered an alternative utility func-
tion
u(Σt) = −
K∑
a=1
{
Var(γa|Σt) + w ×
(
Var(γ1,a|Σt) + Var(γ2,a|Σt)
)}
, (14)
where γa is the difference between arm a > 0 and the control arm in the
probability of an individual’s positive response on both endpoints.
Simulation Study: We discuss a simulation study for a multi-arm trial
with four experimental arms and an overall sample size of T = 348 patients.
For the arms a = 0, 2, 3, 4 the parameters θa = (0.15, 0.25, 0.4, 0.2) are iden-
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tical across the four scenarios that we considered. In Scenario 1, arm a = 1
has no PTE while in Scenarios 2–4 (γ1,1, γ2,1) = (0.2, 0.2), (0.2, 0.05), and
(0.05, 0.2) respectively.
Table ?? in the supplementary material, illustrates the MSE of the ef-
fects estimates γ̂`,a, power for null hypotheses H`0,a : γ`,a ≤ 0, ` = 1, 2
and the proportion of simulations in which both hypotheses are rejected
for BUD designs with utility function (13) (BUD1) or utility function (14)
(BUD2). We also compared BUD designs to a balanced randomized (BR)
design that assigns patients to treatments with equal probabilities. As ex-
pected, the BUD2 design, which seeks to minimize the posterior variance
of the treatment effects, attains the lowest MSEs. The BUD designs have
nearly identical power and BR has across all alternative scenarios the lowest
power.
We also computed the Bayesian optimal design d? using BI with utility
defined by (13) for a trial with K = 2 experimental arms. We compare
the expected utility of the optimal design d? to the expected utility of the
BUD and BR designs d = dBUD, dBR. Expected utilities are computed
by integrating with respect to the prior. With co-primary endpoints dy-
namic programming becomes quickly computationally challenging for mod-
erate sample sizes T ≈ 25, and realistic sample sizes T ≈ 378 are infeasible.
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For values of T = 5, 10, 15, we observe a reduction of expected utility equal
to (0.59%, 1.21%, 2.04%) for BUD and (36.92%, 61.39%, 77.4%) for BR.
6 Discussion
There are competing objectives in the design of clinical trials. These include
identification of treatment effects, accurate estimates, and limiting the num-
ber of patients exposed to suboptimal treatments. Bayesian adaptive designs
usually target the latter aim, or attempt to balance competing aims, by un-
balancing randomization toward more promising arms. In contrast, BUD
designs target an information measure u consistent with the goal of testing
or estimating treatment effects.
Bayesian adaptive randomization (BAR) has been applied in various
clinical studies and, in several settings, it has better operating characteristics
than alternative designs [4, 35, 21, 38, 12, 39]. Limitations of BAR have
also been discussed in the literature. It is known, for example, that in two-
arm trials BAR may increase the overall sample size compared to balanced
randomization (Korn and Freindlin, 2011). In multi-arm trials BAR can be
highly variable in the arm-specific enrollment proportions and in some cases
assigns with non negligible probability more patients to inferior arms than
balanced randomization [35, 32]. This suggests that investigating alternative
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approaches to Bayesian adaptive trials, such as BUD designs, remains a
relevant problem.
Both, BAR and BUD designs translate posterior distributions into ran-
domization probabilities. These two approaches can also be described as
randomized myopic decision rules. BAR approximately optimizes the num-
ber of positive outcomes [4], while BUD designs approximately optimizes
posterior summaries, such as the variance or entropy, that quantify uncer-
tainty on key parameters. In the two-arm case, [4] showed that BAR has, in
several scenarios, operating characteristics similar to the Bayesian optimal
design when the utility function coincides with the number of positive out-
comes. Unlike BAR, BUD designs focus on information measures based on
the primary aims of the trial, such as testing efficacy or estimating treatment
effects.
We propose several information measures which reflect the aims of multi-
arm trials with biomarker subpopulations and multiple endpoints, and show
that in a number of simulation scenarios, frequentist operating character-
istics are improved with respect to other strategies. In fact, the utility
at the end of the experiment is often near the optimal value produced by
intractable backward induction algorithms. The simplicity of the random-
ization probabilities makes it possible to derive asymptotic limits in certain
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examples.
The computing time to simulate a BUD trial increases linearly with re-
spect to the sample size T and with respect to the number of possible actions.
In our examples the computing time for BUD simulations, as expected, is
very similar to BAR, and generally significantly faster than computing the
optimal Bayesian design obtained with dynamic programming.
A crucial aspect of BUD designs is the selection of information metrics
u that represent the primary aims of the clinical study. We can classify
studies into broad categories based on their primary aims; (i) estimating
treatment effects, (ii) identifying therapies with positive effects, and (iii)
studies with multiple objectives, for instance identifying relevant treatment
effects on multiple endpoints or within subgroups.
In case (i), the focus is on key parameters of interest and a symmetric
uncertainty metric, such as the entropy or posterior variance, can be used to
represent estimation accuracy. The sensitivity analyses in Section 3.2 shows
that BUD designs with these information metrics have similar operating
characteristics.
In case (ii), as in hypothesis testing, the parameter space is partitioned
into regions with and without treatment effects. We can use discrete ran-
dom variables Ea ∈ {0, 1} or monotone functions g(γa) representative of this
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partition. The posterior variance or (asymmetric) entropy of these random
variables can be used to define uncertainty measures. For example, in a
multi-arm study with two experimental drugs and binary response to treat-
ment, γa = θa−θ0, a = 1, 2 indicate the difference between the response rate
of experimental arm a and the control. The entropy of Ea = I(γa > 0) or
variance of g(γa) = γa/(1 + γ
2
a)
1/2 can be adopted as uncertainty metrics.
In case (iii), when the study has multiple related goals, a composite
information measure u =
∑
j wjuj can be used to weight different criteria
uj . For example in Section 5, the BUD design for a trial with two endpoints
is based on a composite utility function.
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Figure 1: Comparison of a Bayesian uncertainty directed (BUD) design
and Bayesian adaptive randomization (BAR). We consider an early stage
3-arm trial without control, with the primary goal of selecting the best
experimental arm a? = arg maxa=1,2,3 θa. The total sample size is equal to
T = 100. BAR defines randomization probabilities to treatments a = 1, 2, 3
that mirror the posterior distribution of a∗ [36]. The BUD design randomizes
patients with the goal of approximately minimizing the posterior entropy
of a?. Panels (a), (b) and (c) show three different simulations of the 3-
arm trial after the enrollment of 50 patients. The blue curves show the
posterior densities of the response probabilities θa. The red curves indicate
the posterior distribution of the maximum θa? = maxa=1,2,3 θa. In each panel
we also indicate for BAR and BUD designs the randomization probabilities
of the next patient t = 51 that will be enrolled in the trial.
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Figure 2: Information collected at the end of a multi-arm clinical trial with
four experimental arms. Results are based on 5,000 simulations of a clini-
cal study with four experimental arms using balanced randomization (BR),
Bayesian uncertainty directed (BUD) design, Bayesian adaptive randomiza-
tion (BAR) and two versions of the doubly adaptive coin design (DBCD1
and DBCD2). The top panel shown for each of the four designs the regret
function, which is defined as the difference between the expected information
E[u(ΣT )] of the design and the expected information of the oracle design for
different values of T = 1, 2, . . . , 200. The bottom panel shows boxplots of
the utility u(Σt) =
∑K
k=1
(
vk −Var(γk | Σt)
)
, with prior variance vk, across
the simulated trials for a sample size of T = 336.
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Control Arm 1 Arm 2 Arm 3
Design ESS (SD) ESS (SD) Power MSE ESS (SD) Power MSE ESS (SD) Power MSE
Scenario 1: no effective arm (θ0, θ1, θ2, θ3) = (0.4, 0.4, 0.4, 0.4)
BR 84 (8) 84 (08) 04.0 5.89 84 (8) 04.1 5.86 84 (8) 03.2 5.74
BUD 118 (3) 73 (03) 03.8 5.44 73 (3) 03.8 5.43 73 (3) 04.0 5.52
BAR 97 (8) 80 (21) 03.9 7.33 79 (21) 03.6 7.30 80 (21) 03.8 7.28
BAR2 84 (23) 84 (22) 03.9 7.26 84 (22) 04.0 7.17 84 (23) 04.2 7.37
DBCD1 84 (4) 84 (4) 03.8 5.93 84 (4) 03.8 5.85 84 (4) 03.6 5.82
DBCD2 84 (6) 84 (6) 03.6 5.89 84 (6) 03.9 5.92 84 (6) 03.5 5.82
Scenario 2: one superior arm (θ0, θ1, θ2, θ3) = (0.4,0.6, 0.4, 0.4)
BR 85 (8) 84 (8) 78.6 5.75 83 (8) 04.2 5.75 84 (8) 03.3 5.80
BUD 118 (3) 73 (3) 82.2 5.48 73 (3) 03.6 5.46 73 (3) 03.8 5.40
BAR 100 (10) 103 (14) 87.5 4.89 67 (18) 03.2 7.65 66 (18) 03.6 7.96
BAR2 58 (17 ) 161 (28) 85.1 6.80 58 (17) 3.4 9.80 58 (17) 3.5 9.65
DBCD1 84 (4) 84 (4) 79.8 5.99 84 (4) 03.9 6.07 84 (4) 04.0 6.02
DBCD2 80 (6) 97 (6) 81.2 5.63 80 (6) 03.4 6.16 80 (6) 03.7 6.09
Scenario 3: one superior and one inferior arm (θ0, θ1, θ2, θ3) = (0.4,0.6, 0.4, 0.2)
BR 84 (8) 84 (8) 78.9 5.92 84 (8) 03.6 5.70 84 (8) 0.00 4.72
BUD 122 (4) 75 (3) 84.3 5.10 75 (3) 03.6 5.22 63 (5) 0.00 4.68
BAR 111 (10) 117 (13) 90.6 4.40 75 (20) 04.0 7.22 32 (11) 0.00 8.12
BAR2 62(18) 180 (27) 88.2 6.24 62 (18) 3.4 9.04 31 (8) 0.0 9.95
DBCD1 88 (4) 88 (4) 81.1 5.69 88 (4) 03.7 5.66 72 (7) 0.00 5.20
DBCD2 85 (7) 104 (6) 83.8 5.25 85 (7) 03.8 5.95 61 (8) 0.00 5.76
Scenario 4: three superior arms (θ0, θ1, θ2, θ3) = (0.4,0.6,0.65,0.7)
BR 84 (8) 85 (8) 79.4 5.89 84 (8) 92.5 5.86 84 (8) 98.6 5.74
BUD 120 (3) 74 (3) 83.6 5.34 72 (3) 95.1 5.18 70 (4) 99.1 5.14
BAR 90 (4) 80 (9) 79.2 7.33 82 (8) 93.4 7.30 83 (8) 98.6 7.28
BAR2 35 (10) 75 (22) 55.1 11.94 96 (26) 78.8 10.77 130 (29) 95.3 9.87
DBCD1 86 (4) 86 (4) 80.4 5.93 84 (5) 94.0 5.85 80 (5) 98.6 5.82
DBCD2 70 (6) 85 (5) 75.8 5.89 89 (5) 91.7 5.92 92 (5) 98.4 5.82
Table 1: Expected sample size (ESS), standard deviation (SD), power and mean
squared error (MSE), for each experimental arm in a 4-arm trial with 336 patients
using either balanced randomization (BR), Bayesian uncertainty directed (BUD)
design, Bayesian adaptive randomization (BAR) as described in [38] and the version
described in [35] (BAR2), and two versions of the doubly adaptive biased coin
design, DBCB1 and DBCD2. The MSE is scaled by a factor of 103.
52
Arm 1 Arm 2 Arm 3 Arm 4
T Design ESS (SD) P1 ESS (SD) P2 ESS (SD) P3 ESS (SD) P4 MSE
Scenario 1 (θ1, θ2, θ3, θ4) = (0.3, 0.4, 0.5,0.6)
30 BR 7 (3) 0.059 8 (3) 0.155 8 (2) 0.269 8 (4) 0.517 13.63
BUD 4 (10) 0.035 6 (8) 0.117 8 (10) 0.274 12 (12) 0.573 8.83
BAR 4 (12) 0.044 6 (7) 0.123 8 (7) 0.273 13 (13) 0.560 9.16
RPW 7 (4) 0.056 7 (3) 0.133 8 (3) 0.280 8 (4) 0.531 11.9
50 BR 12 (3) 0.033 13 (3) 0.101 12 (3) 0.276 13 (5) 0.590 9.22
BUD 6 (15) 0.018 9 (12) 0.075 13 (16) 0.247 22 (15) 0.659 6.35
BAR 5 (16) 0.024 8 (15) 0.086 13 (10) 0.251 24 (21) 0.640 6.80
RPW 11 (4) 0.031 12 (4) 0.091 13 (3) 0.2592 14 (6) 0.619 8.23
70 BR 17 (3) 0.015 18 (4) 0.079 17 (4) 0.263 18 (5) 0.643 7.65
BUD 7 (23) 0.008 11 (18) 0.054 18 (20) 0.222 34 (15) 0.715 5.10
BAR 6 (23) 0.011 10 (25) 0.060 18 (16) 0.226 36 (30) 0.703 5.31
RPW 15 (6) 0.013 17 (5) 0.067 18 (4) 0.240 20 (9) 0.680 6.77
Scenario 2 (θ1, θ2, θ3, θ4) = (0.4, 0.4, 0.4,0.8)
30 BR 7 (3) 0.049 8 (3) 0.058 8 (2) 0.040 8 (4) 0.853 13.95
BUD 3 (10) 0.024 4 (11) 0.026 3 (13) 0.028 20 (12) 0.921 11.98
BAR 3 (12) 0.035 3 (8) 0.036 3 (13) 0.033 20 (13) 0.894 13.79
RPW 7 (4) 0.041 7 (2) 0.039 7 (7) 0.041 10 (2) 0.878 13.47
50 BR 12 (3) 0.022 13 (3) 0.022 12 (3) 0.013 13 (5) 0.943 10.94
BUD 4 (17) 0.006 4 (20) 0.008 4 (23) 0.006 37 (20) 0.979 6.33
BAR 4 (20) 0.014 4 (18) 0.016 4 (23) 0.014 38 (22) 0.955 8.11
RPW 11 (4) 0.014 11 (5) 0.013 11 (11) 0.012 17 (4) 0.960 10.03
70 BR 17 (3) 0.007 18 (4) 0.008 17 (4) 0.003 18 (5) 0.982 8.61
BUD 5 (26) 0.002 5 (30) 0.003 5 (33) 0.003 55 (30) 0.992 4.01
BAR 5 (30) 0.006 5 (28) 0.008 4 (33) 0.008 57 (32) 0.977 5.29
RPW 15 (4) 0.005 16 (5) 0.004 15 (15) 0.006 24 (7) 0.984 7.59
Scenario 3 (θ1, θ2, θ3, θ4) = (0.35, 0.45, 0.7,0.8)
30 BR 7 (3) 0.012 8 (3) 0.056 8 (2) 0.314 8 (4) 0.618 8.12
BUD 3 (10) 0.006 3 (8) 0.024 9 (11) 0.290 15 (8) 0.679 8.01
BAR 2 (12) 0.012 3 (10) 0.029 9 (12) 0.306 15 (11) 0.652 8.99
RPW 6 (6) 0.016 6 (3) 0.034 8 (7) 0.315 9 (5) 0.635 8.37
50 BR 12 (3) 0.005 13 (3) 0.021 12 (3) 0.277 13 (5) 0.697 6.57
BUD 3 (13) 0.002 4 (11) 0.006 14 (20) 0.241 28 (15) 0.751 5.11
BAR 3 (22) 0.003 4 (18) 0.011 15 (22) 0.272 28 (19) 0.714 5.86
RPW 10 (9) 0.003 11 (2) 0.014 14 (10) 0.273 16 (7) 0.711 6.43
70 BR 17 (3) 0.001 18 (4) 0.011 17 (4) 0.242 18 (5) 0.747 5.57
BUD 4 (18) 0.001 5 (17) 0.001 19 (26) 0.203 42 (25) 0.795 3.70
BAR 3 (32) 0.001 4 (28) 0.005 20 (32) 0.241 42 (28) 0.752 4.61
RPW 13 (10) 0.001 15 (2) 0.003 20 (14) 0.239 22 (11) 0.757 5.03
Table 2: Expected sample size (ESS), standard deviation (SD), proportion
of simulations that selected therapy a = 1, · · · , 4 as the most effective treat-
ment (Pa) and mean squared error (MSE) of the response rate of the best
arm for 4-arm trial using balanced randomization (BR), Bayesian uncer-
tainty directed (BUD) design, Bayesian adaptive randomization (BAR) and
the randomized play the winner (RPW) design. The overall sample size
equals either T = 30, 50 or 70. Results are based on 10,000 simulated trials.
The MSE is scaled by a factor of 103.
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Expected Sample Size in BMK-positive groups (SD) Power
Biomarker (BMK) 1 2 3 4 Po+ Po−
Scenario 1 arms a = 1, · · · , 4 target BMKs a, BMK prevalence (0.5,0.5,0.5,0.5)
BR each arm 50(7) 50(7) 50(7) 50(7)
BUD control 91 (11) 90(11) 91(11) 91(11)
arm 1 49(30) 37(26) 37(26) 36(26) 10.15 9.96
Scenario 2 arms a = 1, · · · , 4 target BMKs a, BMK prevalence (0.5,0.5,0.5,0.5)
BR control 50(7) 50(7) 50(7) 50(7)
arm 1 50(7) 50(7) 50(7) 50(7) 77.09 9.97
arm 2 50(7) 50(7) 50(7) 50(7) 9.98 9.80
BUD control 90(12) 90(11) 90(10) 90(10)
arm 1 47(29) 38(24) 38(24) 38(23) 86.92 10.00
arm 2 37(26) 49(30) 37(26) 38(26) 10.35 10.92
Scenario 3 arms a = 1, · · · , 4 target BMKs a, BMK prevalence (0.7,0.3,0.5,0.5)
BR control 70(8) 30(5) 50(7) 50(7)
arm 1 70(8) 30(5) 50(7) 50(7) 86.47 10.44
arm 2 70(8) 30(5) 50(7) 50(7) 61.29 10.40
arm 3 70(8) 30(5) 50(7) 50(7) 9.86 10.24
BUD control 120(13) 57(8) 89(10) 89(10)
arm 1 52(33) 16(11) 34(21) 34(21) 92.52 10.81
arm 2 59(32) 35(18) 38(22) 38(22) 75.82 10.28
arm 3 60(38) 21(16) 51(30) 39(26) 9.87 9.44
Scenario 4 arms 1, 2, 3, 4 target BMKs 1, 1, 2, 3, BMK prevalence (0.5,0.5,0.5)
BR control 50(7) 50(7) 50(7)
arm 1 50(7) 50(7) 50(7) 76.90 10.41
arm 2 50(7) 50(7) 50(7) 96.15 10.53
arm 3 50(7) 50(7) 50(7) 10.08 10.61
BUD control 89(11) 90(11) 90(11)
arm 1 47(27) 38(22) 38(22) 87.45 10.30
arm 2 28(18) 26(16) 26(16) 97.17 10.37
arm 3 43(30) 54(30) 41(28) 10.43 9.13
Scenario 5 arms 1,2,3,4 target BMKs 1,1,2,2, BMK prevalence (0.5,0.6)
BR control 50(7) 60(7)
arm 1 50(7) 60(7) 59.41 59.69
arm 2 50(7) 60(7) 76.51 10.54
arm 3 50(7) 60(7) 81.93 10.07
arm 4 50(7) 60(7) 97.76 10.57
BUD control 85(10) 102(11)
arm 1 38(23) 52(27) 61.78 67.99
arm 2 52(24) 62(30) 89.04 9.87
arm 3 45(23) 54(27) 92.48 9.98
arm 4 30(17) 29(17) 98.52 9.71
Table 3: Average sample size, standard deviation (SD) and power in the biomarker
positive (targeted) and negative subgroups (Po+ and Po−) for a 5-arm trial with
an overall sample size of T = 500. Results are based on 5,000 simulations of a
trial using either BUD or BR designs. For each scenario, the patients’ biomarker
status has been generated independently for each marker according to the specified
prevalences. The response rate for the control therapy is constant across scenarios
and equal to 0.35. The first three scenarios refer to a trial with four biomarkers,
and therapy a = 1 (scenarios 2,3) and a = 2 (scenario 3) have a positive treatment
effect (PTE) for patients with biomarkers Xi,a = 1. Scenarios 4 and 5 correspond
to a trial with three and two biomarkers respectively. Therapies a = 1, 2 in Scenario
4 have PTEs for patients with Xi,a = 1. In scenario 5 all therapies a = 2, 3, 4 have
a PTE in their target population, and arm a = 1 PTEs extend to all patients.
